Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib ...Sacramento BeeThe Phase 3 DECISION data will form the basis for regulatory submissions of sorafenib for the treatment of RAI-refractory differentiated thyroid cancer. Submission of a supplemental New Drug Application (sNDA) in the United States is planned for mid ...
http://www.sacbee.com/2013/06/02/5464658/phase-3-decision-trial-investigating.html
No comments:
Post a Comment